How to Invest in Healthcare Stocks and ETFs

Disclosure: This post may contain affiliate links. ZarWealth may earn a commission if you sign up or purchase through our links, at no extra cost to you.

📚 Part of our Complete Investing Guide

Healthcare is the only sector in the S&P 500 that benefits structurally from two unstoppable trends at once: an aging population in every developed economy and the accelerating cost of medical innovation. In 2026 the sector accounts for about 18% of U.S. GDP and around 13% of the S&P 500 by market cap — and unlike technology, the underlying demand barely flinches in a recession. People still need their statins, their oncology drugs, and their surgeries when the stock market falls 30%.

This guide walks through the four sub-sectors inside healthcare, the simplest ETFs to gain exposure, which individual stocks are core holdings versus speculative bets, and the regulatory and pricing risks that have wiped out individual investors who bought the wrong names at the wrong time.

Why healthcare belongs in most long-term portfolios

Three structural tailwinds make healthcare unusual among equity sectors:

• Demographic tailwind. The 65+ population in the U.S. will grow roughly 40% by 2040. Older patients spend three to five times more per year on healthcare than younger ones.
• Defensive cash flows. The MSCI USA Health Care index has fallen less than the S&P 500 in every recession since 1990, with an average drawdown roughly 30% smaller during the 2008 and 2020 sell-offs.
• Innovation pipeline. Roughly $250 billion in global R&D is now flowing into the sector annually, with weight-loss drugs, gene editing, and AI-assisted diagnostics producing genuine multi-billion-dollar product categories.

The trade-off is that the sector is also politically exposed in a way that, say, consumer staples is not. Drug pricing legislation, Medicare reimbursement changes, and patent expirations have produced 30% single-name drawdowns in stocks that looked perfectly safe twelve months earlier.

For a refresher on sector-level allocation decisions and how to weight a thematic sleeve like healthcare against a broad core, see our explainer on sector investing.

The four sub-sectors and how they differ

"Healthcare" is shorthand for four very different businesses. Mixing them up is the most common mistake retail investors make.

| Sub-sector | Examples | Risk profile | |

| Pharma (large cap) | Eli Lilly, J&J, Merck, Pfizer | Moderate — patent cliff risk | |
| Biotech | Vertex, Regeneron, plus 200+ small caps | High — single trial can swing 50% | |
| Medical devices | Intuitive Surgical, Medtronic, Stryker | Moderate — steady consumables | |
| Insurance / providers | UnitedHealth, Elevance, HCA | Moderate — regulatory exposure | |

A pharma stock with a strong product portfolio and a biotech start-up burning cash on Phase II trials are not the same investment, even though they share a sector label. The sub-sector tilt is the single most important decision you will make inside the healthcare allocation.

The three ETFs most retail investors actually need

For 90% of investors, healthcare exposure is best achieved with one or two broad ETFs rather than individual stock picking. Here are the three to know:

• XLV — Health Care Select Sector SPDR. Tracks the healthcare slice of the S&P 500. Expense ratio 0.09%. Top holdings: Eli Lilly, J&J, UnitedHealth. The default core healthcare ETF.
• VHT — Vanguard Health Care. Broader (450+ holdings vs. ~60 in XLV) and slightly cheaper at 0.10%. Better for a "set and forget" allocation.
• IBB — iShares Biotechnology. Pure biotech exposure for investors who want the higher-risk innovation tail. Much more volatile — historical drawdowns over 40%.

A balanced retail allocation might be 70% VHT (broad core) + 30% IBB (innovation tilt). Or simply 100% VHT and accept slightly lower upside in exchange for lower volatility.

If you are still deciding between holding broad index ETFs versus tilting into sectors at all, the trade-offs are worked through in our piece on total market ETFs.

Individual stocks: which are core and which are bets

If you do want to own healthcare names directly, the discipline is to separate compounders from speculative trades. A compounder is a profitable business with a wide moat, growing earnings, and a 10-year track record. A speculative trade is a binary outcome that depends on a single clinical trial or regulatory decision.

• Core compounders. Eli Lilly, UnitedHealth, Intuitive Surgical, Stryker. These have produced 12-15% annualized returns over 20-year windows and pay dividends that grow each year.
• Steady cash cows. Johnson & Johnson, Merck, AbbVie. Slower growth but high dividend yields, useful in a tax-advantaged account.
• Speculative. Pre-revenue biotechs. Position-size at 1-2% of your portfolio each — total speculative sleeve never above 10%.

The mistake to avoid: piling 20% of net worth into a single small-cap biotech because the story sounds compelling. The base rate for any individual Phase II drug reaching approval is roughly 30%, and the base rate of approved drugs producing real revenue at scale is lower still.

The four risks that have burned retail investors

- **Patent cliffs.** A blockbuster drug losing patent protection can take 80% of its revenue in 18 months. Always check the patent expiration calendar before buying large-cap pharma. - **Clinical trial failures.** A failed Phase III trial routinely drops a biotech 40-70% in a single session. Diversify within biotech via IBB if you cannot tolerate that. - **Pricing legislation.** Drug-pricing reform in the U.S. has created 10-20% sector drawdowns three times since 2017. Holding only U.S. pharma names amplifies this exposure. - **Reimbursement changes.** Medicare and private-insurer reimbursement rules quietly determine the profit margins of insurers, hospitals, and device makers. Always read the operating-margin trend over five years, not just the latest quarter.

How much of your portfolio should be in healthcare?

For most long-term retail investors, the practical answer is between 8% and 15% of equity allocation in healthcare — slightly above the market-cap weight of around 13%. This is a sector worth tilting toward, but the tilt should be modest. The single biggest factor mistake is owning 30-40% in healthcare because the narrative sounds bulletproof. Sector concentration risk is real, and even healthcare has had decade-long underperformance stretches.

If you are still building your core position before considering sector tilts, see our roadmap for investing in index funds as the base layer.

The books worth reading on sector investing

Healthcare investing benefits from the same fundamentals as any other equity work. These three books cover the analytical foundations.

📚 Recommended reading for sector and stock investing

• One Up on Wall Street by Peter Lynch — the playbook for investing in what you understand, with several chapters on the healthcare names Lynch rode at Magellan Fund. The framework still works.
• The Intelligent Investor by Benjamin Graham — the foundational text on separating compounders from speculation, with a margin-of-safety framework that fits perfectly with pharma valuation.
• A Random Walk Down Wall Street by Burton Malkiel — the case for why most investors should default to broad ETFs over individual stock picking, written by a Princeton economist with five decades of updates.
• 🎧 Prefer to listen? Try Audible free for 30 days and get any of these as an audiobook on the house.

Want the full picture? Read the Complete Investing Guide →

📋 The FI Checklist

Track your path to financial independence with our free FI Checklist — a one-page printable covering every step from emergency fund to 25x annual expenses.

Disclosure: ZarWealth uses Amazon and other affiliate links throughout this article. We receive a small commission on qualifying purchases, at no additional cost to you. This helps keep ZarWealth free of paywalls and intrusive ads. Always do your own research before investing.